232 related articles for article (PubMed ID: 12052859)
1. Mouse model for human arginase deficiency.
Iyer RK; Yoo PK; Kern RM; Rozengurt N; Tsoa R; O'Brien WE; Yu H; Grody WW; Cederbaum SD
Mol Cell Biol; 2002 Jul; 22(13):4491-8. PubMed ID: 12052859
[TBL] [Abstract][Full Text] [Related]
2. Lethal phenotype in conditional late-onset arginase 1 deficiency in the mouse.
Kasten J; Hu C; Bhargava R; Park H; Tai D; Byrne JA; Marescau B; De Deyn PP; Schlichting L; Grody WW; Cederbaum SD; Lipshutz GS
Mol Genet Metab; 2013 Nov; 110(3):222-30. PubMed ID: 23920045
[TBL] [Abstract][Full Text] [Related]
3. Inducible arginase 1 deficiency in mice leads to hyperargininemia and altered amino acid metabolism.
Sin YY; Ballantyne LL; Mukherjee K; St Amand T; Kyriakopoulou L; Schulze A; Funk CD
PLoS One; 2013; 8(11):e80001. PubMed ID: 24224027
[TBL] [Abstract][Full Text] [Related]
4. Increased plasma and tissue guanidino compounds in a mouse model of hyperargininemia.
Deignan JL; Marescau B; Livesay JC; Iyer RK; De Deyn PP; Cederbaum SD; Grody WW
Mol Genet Metab; 2008 Feb; 93(2):172-8. PubMed ID: 17997338
[TBL] [Abstract][Full Text] [Related]
5. Myocyte-mediated arginase expression controls hyperargininemia but not hyperammonemia in arginase-deficient mice.
Hu C; Kasten J; Park H; Bhargava R; Tai DS; Grody WW; Nguyen QG; Hauschka SD; Cederbaum SD; Lipshutz GS
Mol Ther; 2014 Oct; 22(10):1792-802. PubMed ID: 24888478
[TBL] [Abstract][Full Text] [Related]
6. Arginase deficiency manifesting delayed clinical sequelae and induction of a kidney arginase isozyme.
Grody WW; Kern RM; Klein D; Dodson AE; Wissman PB; Barsky SH; Cederbaum SD
Hum Genet; 1993 Mar; 91(1):1-5. PubMed ID: 8454280
[TBL] [Abstract][Full Text] [Related]
7. Short-term correction of arginase deficiency in a neonatal murine model with a helper-dependent adenoviral vector.
Gau CL; Rosenblatt RA; Cerullo V; Lay FD; Dow AC; Livesay J; Brunetti-Pierri N; Lee B; Cederbaum SD; Grody WW; Lipshutz GS
Mol Ther; 2009 Jul; 17(7):1155-63. PubMed ID: 19367256
[TBL] [Abstract][Full Text] [Related]
8. Minimal ureagenesis is necessary for survival in the murine model of hyperargininemia treated by AAV-based gene therapy.
Hu C; Tai DS; Park H; Cantero G; Cantero-Nieto G; Chan E; Yudkoff M; Cederbaum SD; Lipshutz GS
Gene Ther; 2015 Feb; 22(2):111-5. PubMed ID: 25474440
[TBL] [Abstract][Full Text] [Related]
9. Ornithine deficiency in the arginase double knockout mouse.
Deignan JL; Livesay JC; Yoo PK; Goodman SI; O'Brien WE; Iyer RK; Cederbaum SD; Grody WW
Mol Genet Metab; 2006; 89(1-2):87-96. PubMed ID: 16753325
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival of the juvenile lethal arginase-deficient mouse with AAV gene therapy.
Lee EK; Hu C; Bhargava R; Rozengurt N; Stout D; Grody WW; Cederbaum SD; Lipshutz GS
Mol Ther; 2012 Oct; 20(10):1844-51. PubMed ID: 22760543
[TBL] [Abstract][Full Text] [Related]
11. Human recombinant arginase enzyme reduces plasma arginine in mouse models of arginase deficiency.
Burrage LC; Sun Q; Elsea SH; Jiang MM; Nagamani SC; Frankel AE; Stone E; Alters SE; Johnson DE; Rowlinson SW; Georgiou G; ; Lee BH
Hum Mol Genet; 2015 Nov; 24(22):6417-27. PubMed ID: 26358771
[TBL] [Abstract][Full Text] [Related]
12. Arginases I and II: do their functions overlap?
Cederbaum SD; Yu H; Grody WW; Kern RM; Yoo P; Iyer RK
Mol Genet Metab; 2004 Apr; 81 Suppl 1():S38-44. PubMed ID: 15050972
[TBL] [Abstract][Full Text] [Related]
13. Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency.
Truong B; Allegri G; Liu XB; Burke KE; Zhu X; Cederbaum SD; Häberle J; Martini PGV; Lipshutz GS
Proc Natl Acad Sci U S A; 2019 Oct; 116(42):21150-21159. PubMed ID: 31501335
[TBL] [Abstract][Full Text] [Related]
14. Strategies to rescue the consequences of inducible arginase-1 deficiency in mice.
Ballantyne LL; Sin YY; St Amand T; Si J; Goossens S; Haenebalcke L; Haigh JJ; Kyriakopoulou L; Schulze A; Funk CD
PLoS One; 2015; 10(5):e0125967. PubMed ID: 25938595
[TBL] [Abstract][Full Text] [Related]
15. Arginase induction by sodium phenylbutyrate in mouse tissues and human cell lines.
Kern RM; Yang Z; Kim PS; Grody WW; Iyer RK; Cederbaum SD
Mol Genet Metab; 2007 Jan; 90(1):37-41. PubMed ID: 16935537
[TBL] [Abstract][Full Text] [Related]
16. Arginase expression in mouse embryonic development.
Yu H; Iyer RK; Yoo PK; Kern RM; Grody WW; Cederbaum SD
Mech Dev; 2002 Jul; 115(1-2):151-5. PubMed ID: 12049781
[TBL] [Abstract][Full Text] [Related]
17. Delivery of cytosolic liver arginase into the mitochondrial matrix space: a possible novel site for gene replacement therapy.
Wissmann PB; Goodman BK; Vockley JG; Kern RM; Cederbaum SD; Grody WW
Somat Cell Mol Genet; 1996 Nov; 22(6):489-98. PubMed ID: 9131018
[TBL] [Abstract][Full Text] [Related]
18. Arginase-1 deficiency.
Sin YY; Baron G; Schulze A; Funk CD
J Mol Med (Berl); 2015 Dec; 93(12):1287-96. PubMed ID: 26467175
[TBL] [Abstract][Full Text] [Related]
19. AAV-based gene therapy prevents neuropathology and results in normal cognitive development in the hyperargininemic mouse.
Lee EK; Hu C; Bhargava R; Ponnusamy R; Park H; Novicoff S; Rozengurt N; Marescau B; De Deyn P; Stout D; Schlichting L; Grody WW; Cederbaum SD; Lipshutz GS
Gene Ther; 2013 Aug; 20(8):785-96. PubMed ID: 23388701
[TBL] [Abstract][Full Text] [Related]
20. Hyperargininemia due to arginase I deficiency: the original patients and their natural history, and a review of the literature.
Schlune A; Vom Dahl S; Häussinger D; Ensenauer R; Mayatepek E
Amino Acids; 2015 Sep; 47(9):1751-62. PubMed ID: 26123990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
